scholarly journals Effects of combined therapy of ACE inhibitor and exercise on cardiovascular functions and morphology of the heart and kidneys in SHR

2019 ◽  
Vol 8 (5) ◽  
pp. 229-240 ◽  
Author(s):  
Masato Suzuki ◽  
Noriko Hozumi ◽  
Hidefumi Waki ◽  
Masaki Kimura ◽  
Tetsuya Seino ◽  
...  
Keyword(s):  
Ace Inhibitor ◽  
Combined Therapy ◽  
Morphology Of The Heart ◽  
Cardiovascular Functions

scholarly journals Effects of combined therapy of ACE inhibitor and exercise on the development of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats

2020 ◽  
Vol 9 (5) ◽  
pp. 235-246
Author(s):  
Shinichiro Aoyama ◽  
Daisuke Shindo ◽  
Junichi Otsuka ◽  
Eriko Matsuo ◽  
Shigeru Matsubara ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Ace Inhibitor ◽  
Combined Therapy ◽  
Long Evans

Combined Therapy with Benazepril and Amlodipine in the Treatment of Hypertension Inadequately Controlled by an ACE Inhibitor Alone

1997 ◽  
Vol 30 (4) ◽  
pp. 497-503 ◽  
Author(s):  
Roberto Fogari ◽  
Luigi Corea ◽  
Ondina Cardoni ◽  
Franco Cosmi ◽  
Carlo Porcellati ◽  
...  
Keyword(s):  
Ace Inhibitor ◽  
Combined Therapy ◽  
Treatment Of Hypertension

Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes

2011 ◽  
Vol 301 (5) ◽  
pp. F1114-F1123 ◽  
Author(s):  
Carla Zoja ◽  
Sara Cattaneo ◽  
Fabio Fiordaliso ◽  
Vincenzo Lionetti ◽  
Vanessa Zambelli ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Drug Combination ◽  
Ace Inhibitor ◽  
Combined Therapy ◽  
Capillary Density ◽  
Ang Ii ◽  
Monocyte Chemoattractant Protein 1 ◽  
Eta Receptor Antagonist

Diabetic nephropathy is associated with cardiovascular morbidity. Angiotensin-converting enzyme (ACE) inhibitors provide imperfect renoprotection in advanced type 2 diabetes, and cardiovascular risk remains elevated. Endothelin (ET)-1 has a role in renal and cardiac dysfunction in diabetes. Here, we assessed whether combination therapy with an ACE inhibitor and ETA receptor antagonist provided reno- and cardioprotection in rats with overt type 2 diabetes. Four groups of Zucker diabetic fatty (ZDF) rats were treated orally from 4 (when proteinuric) to 8 mo with vehicle, ramipril (1 mg/kg), sitaxsentan (60 mg/kg), and ramipril plus sitaxsentan. Lean rats served as controls. Combined therapy ameliorated proteinuria and glomerulosclerosis mostly as a result of the action of ramipril. Simultaneous blockade of ANG II and ET-1 pathways normalized renal monocyte chemoattractant protein-1 and interstitial inflammation. Cardiomyocyte loss, volume enlargement, and capillary rarefaction were prominent abnormalities of ZDF myocardium. Myocyte volume was reduced by ramipril and sitaxsentan, which also ameliorated heart capillary density. Drug combination restored myocardial structure and reestablished an adequate capillary network in the presence of increased cardiac expression of VEGF/VEGFR-1, and significant reduction of oxidative stress. In conclusion, in type 2 diabetes concomitant blockade of ANG II synthesis and ET-1 biological activity through an ETA receptor antagonist led to substantial albeit not complete renoprotection, almost due to the ACE inhibitor. The drug combination also showed cardioprotective properties, which however, were mainly dependent on the contribution of the ETA receptor antagonist through the action of VEGF.

Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet

2002 ◽  
Vol 22 (4) ◽  
pp. 349-352 ◽  
Author(s):  
Emile Hay ◽  
Hashmonai Derazon ◽  
Natalia Bukish ◽  
Leonid Katz ◽  
Igor Kruglyakov ◽  
...  
Keyword(s):  
Ace Inhibitor ◽  
Combined Therapy ◽  
Cox 2

scholarly journals Effectiveness and safety of the ACE inhibitor and diuretic combination in postmenopausal women with arterial hypertension

2011 ◽  
Vol 10 (3) ◽  
pp. 35-39
Author(s):  
G. G. Semenkova ◽  
E. E. Matvienko
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Postmenopausal Women ◽  
Ace Inhibitor ◽  
Comparison Group ◽  
Combined Therapy ◽  
Modified Release

Aim. To assess effectiveness, tolerability, and safety of combined antihypertensive therapy (AHT) with an ACE inhibitor (perindopril) and thiazide-like diuretic (indapamide) in postmenopausal women with arterial hypertension (AH). Material and methods. This open, one-centre study included 43 postmenopausal women with AH. For 3 months, the patients in the main group (MG; n=22) received indapamide MR (modified release) (1,5 mg/d) and perindopril. The comparison group (CG; n=21) was administered non-MR indapamide (2,5 mg/d) and perindopril. The dynamics of office blood pressure (BP) levels, 24-hour BP monitoring parameters, laboratory parameters, quality of life (QoL), as well as therapy safety and tolerability, was assessed. Results. In both groups, the treatment was clinically effective, safe, and QoL-improving. Target BP levels were achieved in the majority of the patients: 85,3 % and 72,4 % in the MG and CG, respectively. The combination therapy including indapamide MR provided greater improvement of circadian BP rhythm, larger reduction in both morning BP surge and increased BP variability, as well as target BP achievement in higher proportion of the patients. Conclusion. In postmenopausal women with AH, combined therapy with perindopril and indapamide MR provided more benefits, compared to the treatment with perindopril and non-MR indapamide.

scholarly journals Modern approaches to combined therapy of arterial hypertension

2013 ◽  
Vol 10 (4) ◽  
pp. 44-49
Author(s):  
D A Napalkov ◽  
A V Zhilenko
Keyword(s):  
Blood Pressure ◽  
Calcium Antagonist ◽  
Arterial Hypertension ◽  
High Blood Pressure ◽  
Ace Inhibitor ◽  
Combined Therapy ◽  
European Guidelines

The article discusses some of the changes in the 2013 European Guidelines in comparison with the previous revision with an emphasis on practical activities of cardiologists and therapists as well as the combined therapy of high blood pressure. Also, special attention is paid to one of the preferred combinations of antihypertensives – a combination of ACE inhibitor and calcium antagonist and, in particular perindopril and amlodipine.

scholarly journals Evaluation of the effectiveness of drug treatment in patients with arterial hypertension and insomnia

2021 ◽  
Vol 2 (4) ◽  
pp. 49-59
Author(s):  
I. N. Vasilieva ◽  
A. I. Chesnikova ◽  
O. S. Klimenkova ◽  
A. M. Bikmetova
Keyword(s):  
Blood Pressure ◽  
Arterial Hypertension ◽  
Ace Inhibitor ◽  
Combined Therapy ◽  
Blood Pressure Level ◽  
Biological Rhythms ◽  
Initial Therapy ◽  
Clinical State ◽  
Comorbid Condition ◽  
Synthetic Analogue

Objective: chronic sleep disturbance is a comorbid condition with arterial hypertension, often combined with affective disorders, anxiety, depression. Forced sleep deprivation in patients with hypertension indicates a high activity of the renin‑angiotensin‑aldosterone system (RAAS) and desynchronosis of biological rhythms caused by a probable deficit in melatonin secretion during the night. Timely elimination of any pathological process associated with insomnia and arterial hypertension (AH) in the early stages of its development is a prerequisite for the effectiveness of therapy. Therefore, initial therapy should help neutralize the adverse effects of RAAS and improve the 24‑hour blood pressure (BP) profile. The aim of this study was to determine the therapeutic effect of monotherapy with an angiotensin converting enzyme (ACE) inhibitor, As well as in combination with a synthetic analogue of melatonin, on the course of hypertension and parameters of systemic hemodynamics in patients with first degree hypertension with insomnia at the onset of the disease. Combined therapy with an ACE inhibitor and a synthetic analogue of MT in patients with hypertension and insomnia was accompanied by an improvement in the clinical state, achievement of the target blood pressure level in most patients, positive dynamics of central blood pressure parameters and indicators reflecting the rigidity of peripheral arteries.

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes

2009 ◽  
Vol 297 (5) ◽  
pp. F1448-F1456 ◽  
Author(s):  
Elena Gagliardini ◽  
Daniela Corna ◽  
Carla Zoja ◽  
Fabio Sangalli ◽  
Fabiola Carrara ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Receptor Antagonist ◽  
Ace Inhibitor ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Diabetic Rats ◽  
Size Selectivity ◽  
Glomerular Lesions ◽  
Glomerular Size ◽  
And Function

In the present study, we evaluated the effect of simultaneously blocking angiotensin II synthesis and endothelin (ET)-1 activity as a multimodal intervention to implement renoprotection in overt diabetic nephropathy. Mechanisms underlying combined therapy effectiveness were addressed by investigating podocyte structure and function and glomerular barrier size-selective properties. Uninephrectomized rats made diabetic by streptozotocin received orally placebo, lisinopril (12.5 mg/l), the ETA receptor antagonist avosentan (30 mg/kg), or their combination from 4 (when animals had proteinuria) to 8 mo. Proteinuria, renal damage, podocyte number, nephrin expression, and glomerular size selectivity by graded-size Ficoll molecule fractional clearance were assessed. Combined therapy normalized proteinuria, provided complete protection from tubulointerstitial damage, and induced regression of glomerular lesions, while only a partial renoprotection was achieved by each drug alone. Lisinopril plus avosentan restored to normal values the number of podocytes. Single therapies only limited podocyte depletion. Defective nephrin expression of diabetes was prevented by each drug. Altered glomerular size selectivity to large macromolecules of diabetic rats was remarkably improved by lisinopril and the combined treatment. Avosentan ameliorated peritubular capillary architecture and reduced interstitial inflammation and fibrosis. The ACE inhibitor and ETA receptor antagonist induced regression of glomerular lesions in overt diabetic nephropathy. Regression of renal disease was conceivably the result of the synergistic effect of the ACE inhibitor of preserving glomerular permselective properties and the ETA antagonist in improving tubulointerstitial changes. These findings provide mechanistic insights to explain the antiproteinuric effect of this combined therapy in diabetes.

Sign in / Sign up

Export Citation Format

Share Document